
TY  - JOUR
TI  - 2018 ACCP Global Conference on Clinical Pharmacy: October 20–23, 2018
JO  - JACCP:  JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
JA  - J Am Coll Clin Pharm
VL  - 1
IS  - 2
UR  - https://doi.org/10.1002/jac5.1059
DO  - doi:10.1002/jac5.1059
SP  - 122
EP  - 353
PY  - 2018
ER  - 

TY  - JOUR
AU  - Patriarca, Francesca
AU  - Petrucci, Maria T.
AU  - Bringhen, Sara.
AU  - Baldini, Luca
AU  - Caravita, Tommaso
AU  - Corradini, Paolo
AU  - Corso, Alessandro
AU  - Di Raimondo, Francesco
AU  - Falcone, Antonietta
AU  - Ferrara, Felicetto
AU  - Morabito, Fortunato
AU  - Musto, Pellegrino
AU  - Offidani, Massimo
AU  - Petrini, Mario
AU  - Rizzi, Rita
AU  - Semenzato, Gianpietro
AU  - Tosi, Patrizia
AU  - Vacca, Angelo
AU  - Cavo, Michele
AU  - Boccadoro, Mario
AU  - Palumbo, Antonio
TI  - Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
JO  - European Journal of Haematology
VL  - 82
IS  - 2
SN  - 0902-4441
UR  - https://doi.org/10.1111/j.1600-0609.2008.01179.x
DO  - doi:10.1111/j.1600-0609.2008.01179.x
SP  - 93
EP  - 105
KW  - myeloma
KW  - clinical practice guidelines
KW  - chemotherapy
KW  - transplantation
PY  - 2009
AB  - Abstract Purpose and basic procedure of the study:? The availability of new targeted therapies has revolutionised the treatment of multiple myeloma (MM), for both the newly diagnosed and the relapsed and refractory settings. A panel of Italian experts provided guidelines for optimal clinical practice in the treatment of MM. Main findings and conclusions:? The panel recommended that treatment should only be initiated in symptomatic patients. Autologous stem cell transplantation (ASCT) with melphalan is the treatment of choice in patients younger than 65?yr, and induction therapy including new drugs seems the most suitable preparatory regimen before ASCT. In patients who fail to achieve at least a very good partial response (VGPR) after transplant, a consolidation with a second transplant is of clinical benefit. Also, there is evidence that maintenance with thalidomide after ASCT in young patients failing to reach at least VGPR could prolong survival. In elderly patients, the combination of an alkylating drug with a novel agent should be considered as standard approach. Relapsed MM should be retreated after the reappearance of symptoms and signs of organ and tissue damage. Salvage regimens should include corticosteroids plus bortezomib, thalidomide or lenalidomide.
ER  - 

TY  - JOUR
TI  - 28th Annual Meeting of the Wound Healing Society, SAWC-Spring/WHS Joint Meeting: Georgia World Congress Center, Atlanta, Georgia, USA, April 13–17, 2016
JO  - Wound Repair and Regeneration
JA  - Wound Rep Reg
VL  - 24
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/wrr.12405
DO  - doi:10.1111/wrr.12405
SP  - A1
EP  - A34
PY  - 2016
ER  - 

TY  - JOUR
AU  - Ando, Motozumi
AU  - Nakasako, Shinji
AU  - Ariyoshi, Koichi
AU  - Yamaguchi, Marie
AU  - Sakizono, Kenji
AU  - Minowa, Kazushi
AU  - Fukushima, Shoji
AU  - Sugioka, Nobuyuki
AU  - Hashida, Tohru
TI  - Re-elevation of serum amlodipine level after lipid emulsion therapy in an overdose case
JO  - Journal of Clinical Pharmacy and Therapeutics
JA  - J Clin Pharm Ther
VL  - 44
IS  - 6
SN  - 0269-4727
UR  - https://doi.org/10.1111/jcpt.13018
DO  - doi:10.1111/jcpt.13018
SP  - 970
EP  - 973
KW  - amlodipine
KW  - calcium channel antagonist
KW  - emergency
KW  - intravenous lipid emulsion therapy
KW  - liquid chromatography-mass spectrometry
PY  - 2019
AB  - Abstract What is known and objective Amlodipine overdose is common; however, the dose and timing of intravenous lipid emulsion (ILE) therapy as a management strategy remain debatable. Case description A 73-year-old man received a single bolus (1.5 mL/kg) of ILE therapy following massive ingestion of multiple drugs, including amlodipine. After approximately 20 hours of ILE therapy, the serum amlodipine level that had decreased from 90.2 to 49.9 ng/mL increased to 70.8 ng/mL. What is new and conclusion A single bolus (1.5 mL/kg) of ILE therapy is probably insufficient to completely capture and partition serum amlodipine following amlodipine overdose.
ER  - 

TY  - JOUR
TI  - 2014 Annual Meeting of the American Society for Bone and Mineral Research Houston, TX September 12–15, 2014
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 29
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.2476
DO  - doi:10.1002/jbmr.2476
SP  - S1
EP  - S1
PY  - 2014
AB  - ABSTRACT Searchable abstracts may be found at http://www.asbmr.org/education/abstracts
ER  - 

TY  - JOUR
AU  - PICCIN, A.
AU  - O’MARCAIGH, A.
AU  - DEIRATANY, S.
AU  - MC MAHON, C.
AU  - SMITH, O. P.
TI  - Severe gastrointestinal haemorrhage, first manifestation of neonatal haemophilia A
JO  - Haemophilia
VL  - 15
IS  - 3
SN  - 1351-8216
UR  - https://doi.org/10.1111/j.1365-2516.2009.01988.x
DO  - doi:10.1111/j.1365-2516.2009.01988.x
SP  - 817
EP  - 819
PY  - 2009
ER  - 

AU  - Stanworth, Simon J.
AU  - Tinmouth, Alan T.
C7  - pp. 295-301
TI  - Plasma and cryoprecipitate for transfusion
SN  - 9781119012993
UR  - https://doi.org/10.1002/9781119013020.ch26
DO  - doi:10.1002/9781119013020.ch26
SP  - 295-301
KW  - Plasma
KW  - FFP
KW  - cryoprecipitate
KW  - coagulation
PY  - 2009
AB  - Summary General recommendations for plasma transfusion have been well described in many guidelines. Therapeutic uses of plasma, in association with bleeding and abnormalities of coagulation tests (except in emergencies) are based on pathophysiological rationale, but questions about optimal dose and schedule of plasma. A recurring theme in many settings is an overall paucity of high-level evidence to inform optimal plasma transfusion practice remain unanswered, and this particularly applies to prophylactic uses of plasma. There should be more recognition of the limitations of current standard coagulation screening tests, and appreciation that in vitro abnormalities of coagulation screening tests do not equate with an in vivo failure of clinical haemostasis and the presence of clinical coagulopathy. Newer global tests of haemostasis may be better markers of abnormal bleeding risk, but should be assessed and validated in larger clinical studies. Given current evidence, a more appropriate plasma transfusion strategy may be one that emphasises the therapeutic use of plasma in bleeding patients. The role, if any, of prophylactic plasma transfusion in non-bleeding patients with abnormalities of standard coagulation tests, which have limited value in predicting bleeding remains very uncertain. Future research should identify the constituents in plasma that are providing the most benefit (e.g. by analogy the role of ADAMTS13 in TTP). With a better mechanistic understanding of disorders with acquired deficiencies of one or more coagulation factors, replacement might also be more appropriately managed in the future with concentrates of multiple coagulation factors, and which would minimise risks of circulatory overload described when high volume plasma transfusions are given.
ER  - 

TY  - JOUR
TI  - ILTS
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 12
IS  - 5
SN  - 9781119012993
UR  - https://doi.org/10.1002/lt.20832
DO  - doi:10.1002/lt.20832
SP  - C1
EP  - C142
PY  - 2006
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 16
IS  - S3
SN  - 9781119012993
UR  - https://doi.org/10.1111/ajt.13898
DO  - doi:10.1111/ajt.13898
SP  - 405
EP  - 798
PY  - 2016
ER  - 

TY  - JOUR
TI  - E-Posters, EP1
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
JA  - BJOG
VL  - 120
IS  - s1
SN  - 9781119012993
UR  - https://doi.org/10.1111/1471-0528.12293
DO  - doi:10.1111/1471-0528.12293
SP  - 19
EP  - 184
PY  - 2013
ER  - 

TY  - JOUR
AU  - Gulati, Abhishek
AU  - Gerk, Phillip M.
TI  - Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy
JO  - Journal of Pharmaceutical Sciences
JA  - J. Pharm. Sci.
VL  - 98
IS  - 7
SN  - 9781119012993
UR  - https://doi.org/10.1002/jps.21623
DO  - doi:10.1002/jps.21623
SP  - 2317
EP  - 2335
KW  - ABC transporters
KW  - P-glycoprotein
KW  - multidrug resistance-associated proteins
KW  - placenta
KW  - pregnancy
KW  - transporters
KW  - active transport
KW  - efflux pumps
KW  - pharmacokinetics/pharmacodynamics
KW  - multidrug resistance transporters
PY  - 2009
AB  - Abstract Highly active anti-retroviral therapy (HAART) is used to treat HIV-infected patients and involves administration of multiple antiretroviral drugs acting at different steps of the HIV life cycle. In treating HIV-infected pregnant patients, the aim of therapy is not only to treat the mother but also to prevent the transmission of the virus to the fetus. Among the antiretroviral drugs used, there are differences in the extent of transfer of these drugs across the placenta; HIV protease inhibitors are particularly poorly transferred. Activities of ABC transporters expressed in the human placenta as well as differences in plasma protein binding may account for the poor transplacental transfer of certain drugs. This review discusses factors affecting the extent of placental transfer of antiretroviral drugs during pregnancy. These issues may also apply to drugs in other therapeutic categories. ? 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2317?2335, 2009
ER  - 

TY  - JOUR
TI  - Poster Session IV (Abstracts 1638 – 2112)
JO  - Hepatology
JA  - Hepatology
VL  - 64
IS  - S1
SN  - 9781119012993
UR  - https://doi.org/10.1002/hep.28800
DO  - doi:10.1002/hep.28800
SP  - 811
EP  - 1050
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Nephrology
VL  - 15
IS  - s3
SN  - 9781119012993
UR  - https://doi.org/10.1111/j.1440-1797.2010.01337.x
DO  - doi:10.1111/j.1440-1797.2010.01337.x
SP  - 62
EP  - 144
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Absracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 107
IS  - s1
SN  - 9781119012993
UR  - https://doi.org/10.1111/vox.12155
DO  - doi:10.1111/vox.12155
SP  - 57
EP  - 248
PY  - 2014
ER  - 

TY  - JOUR
TI  - Nutrition Practice Abstracts Clinical Nutrition Week
JO  - Nutrition in Clinical Practice
JA  - Nutrition in Clinical Practice
VL  - 26
IS  - 1
SN  - 9781119012993
UR  - https://doi.org/10.1177/0884533610397920
DO  - doi:10.1177/0884533610397920
SP  - 94
EP  - 102
PY  - 2011
ER  - 

TY  - JOUR
TI  - ACRT-SCTS Scholar Abstracts
JO  - Clinical and Translational Science
VL  - 3
IS  - 2
SN  - 9781119012993
UR  - https://doi.org/10.1111/j.1752-8062.2010.00181_2.x
DO  - doi:10.1111/j.1752-8062.2010.00181_2.x
SP  - S8
EP  - S55
PY  - 2010
ER  - 

TY  - JOUR
AU  - Birtch, Alan G.
AU  - Moore, Francis D.
TI  - Experience in Liver Transplantation
JO  - Immunological Reviews
VL  - 2
IS  - 1
SN  - 9781119012993
UR  - https://doi.org/10.1111/j.1600-065X.1969.tb00208.x
DO  - doi:10.1111/j.1600-065X.1969.tb00208.x
SP  - 90
EP  - 128
PY  - 1969
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Urology
JA  - Int. J. Urol.
VL  - 24
IS  - S1
SN  - 9781119012993
UR  - https://doi.org/10.1111/iju.13413
DO  - doi:10.1111/iju.13413
SP  - 4
EP  - 149
PY  - 2017
ER  - 

TY  - JOUR
TI  - Association of Surgeons of Great Britain and Ireland (Edinburgh 2006) abstracts
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 93
IS  - S1
SN  - 9781119012993
UR  - https://doi.org/10.1002/bjs.5436
DO  - doi:10.1002/bjs.5436
SP  - 1
EP  - 100
PY  - 2006
AB  - Abstract The Annual Scientific Meeting of the Association of Surgeons takes place this year at the Edinburgh International Conference Centre (3rd ? 5th May 2006), under the presidency of Mr Denis Wilkins. To view all abstracts from this meeting, please click the pdf link on this page.
ER  - 

TY  - JOUR
AU  - Bambauer, Rolf
TI  - New Approaches in the Treatment of Acute Kidney Injury
JO  - Therapeutic Apheresis and Dialysis
VL  - 13
IS  - 4
SN  - 9781119012993
UR  - https://doi.org/10.1111/j.1744-9987.2009.00719.x
DO  - doi:10.1111/j.1744-9987.2009.00719.x
SP  - 248
EP  - 253
PY  - 2009
ER  - 
